- Home
- CGTX vs IPHA Comparison
CGTX vs IPHA Comparison
Compare CGTX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- IPHA
- Stock Information
- Founded
- CGTX 2007
- IPHA 1999
- Country
- CGTX United States
- IPHA France
- Employees
- CGTX N/A
- IPHA N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- IPHA Health Care
- Exchange
- CGTX Nasdaq
- IPHA Nasdaq
- Market Cap
- CGTX 158.8M
- IPHA 160.1M
- IPO Year
- CGTX 2021
- IPHA 2019
- Fundamental
- Price
- CGTX $1.74
- IPHA $2.16
- Analyst Decision
- CGTX Strong Buy
- IPHA Hold
- Analyst Count
- CGTX 3
- IPHA 2
- Target Price
- CGTX $2.83
- IPHA $2.00
- AVG Volume (30 Days)
- CGTX 2.1M
- IPHA 17.1K
- Earning Date
- CGTX 11-12-2025
- IPHA 09-17-2025
- Dividend Yield
- CGTX N/A
- IPHA N/A
- EPS Growth
- CGTX N/A
- IPHA N/A
- EPS
- CGTX N/A
- IPHA N/A
- Revenue
- CGTX N/A
- IPHA $14,839,695.00
- Revenue This Year
- CGTX N/A
- IPHA $50.89
- Revenue Next Year
- CGTX N/A
- IPHA N/A
- P/E Ratio
- CGTX N/A
- IPHA N/A
- Revenue Growth
- CGTX N/A
- IPHA N/A
- 52 Week Low
- CGTX $0.22
- IPHA $1.29
- 52 Week High
- CGTX $3.83
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CGTX 51.92
- IPHA 60.68
- Support Level
- CGTX $1.67
- IPHA $1.95
- Resistance Level
- CGTX $2.00
- IPHA $2.28
- Average True Range (ATR)
- CGTX 0.16
- IPHA 0.07
- MACD
- CGTX 0.02
- IPHA 0.03
- Stochastic Oscillator
- CGTX 59.48
- IPHA 69.69
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.